Daiichi Sankyo Withdraws Shipment Of Half The Company's Entire Influenza Vaccine Supply
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Daiichi Sankyo Co. Ltd. will trash nearly half of its annual influenza vaccines after tests revealed batches were contaminated by avian reovirus. The company's joint venture with Kitasato Institute for vaccine production has had a rocky start since it began operations March 31, but vaccines play a small role in the company's overall domestic sales, so impact is expected to be negligible
You may also be interested in...
Daiichi Sankyo And GSK Build Japanese Vaccine Firm, While Takeda Expands Abroad
Both Daiichi Sankyo and Takeda claim to have a path for the top vaccine spot in Japan, but all vaccine firms seem poised to benefit from MHLW's more generous attitude toward preventative medicine.
Daiichi Sankyo And GSK Build Japanese Vaccine Firm, While Takeda Expands Abroad
Both Daiichi Sankyo and Takeda claim to have a path for the top vaccine spot in Japan, but all vaccine firms seem poised to benefit from MHLW's more generous attitude toward preventative medicine.
Business Continuity Vital In Japan For Companies Like Daiichi Sankyo On Slow Road To Recovery; Earthquake Impacts Organizational Moves
TOKYO - An emerging view of the damage to pharmaceutical companies in Japan points to a scenario in which affected companies must find a way to ensure business continuity while simultaneously beginning a slow recovery